Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
WEBDec 11, 2019 · Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor–positive, HER2-negative advanced breast cancer.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast ...
WEBFeb 6, 2020 · In a descriptive update, median progression-free survival among patients receiving first-line treatment was 33.6 months (95% CI, 27.1 to 41.3) in the ribociclib group and 19.2 months (95% CI, 14.9 to 23.6) in the placebo group.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
WEBMar 9, 2022 · First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast...
Updated overall survival from the MONALEESA-3 trial in
WEBAug 31, 2023 · This analysis of MONALEESA-3 reports the longest mOS thus far (67.6 months) for 1L patients in a phase III ABC trial. These results in a 1L population show that the OS benefit of ribociclib was maintained through extended follow-up, further supporting its use in HR+/HER2- ABC.
Combination Produces Longest Survival to Date in Treatment …
WEBMay 10, 2022 · Ribociclib plus fulvestrant has produced the longest median overall survival (OS) observed to date in patients with treatment-naïve advanced breast cancer enrolled in a phase 3...
Sustained Survival Benefit with Ribociclib Plus Fulvestrant in Advanced ...
WEBJun 6, 2021 · In an exploratory analysis with an extended follow-up, ribociclib plus fulvestrant showed consistent superior overall survival (OS) benefit in postmenopausal patients with hormone...
Updated Overall Survival of Ribociclib plus Endocrine Therapy …
WEBMar 3, 2022 · Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR +), HER2-negative (HER2 −) advanced breast cancer (ABC). The median OS was not reached in the ...
A randomized, phase II trial of fulvestrant or exemestane with or ...
WEBJun 8, 2022 · Abstract. LBA1004. Background: CDK 4/6i has demonstrated benefit in progression free survival (PFS) and overall survival (OS) in pts with HR+, HER2- MBC when combined with endocrine therapy (ET).
Ribociclib Improves Survival in Advanced Breast Cancer
WEBOct 6, 2021 · Women with metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer overall than women treated with letrozole only, updated results from the MONALEESA-2 …
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival …
WEBOct 10, 2022 · With further follow-up of MONALEESA-3, ribociclib plus fulvestrant achieved a median overall survival of more than 5.5 years (67.6 months) in the first-line setting for postmenopausal women with hormone receptor–positive/HER2 …
Skip to content